RemeGen and Santen Enter into Exclusive Licensing Agreement for Ophthalmic Innovative Drug RC28-E in Greater China and Asian countries
RemeGen Co., Ltd. (Stock Code: 688331.SH/09995.HK, “RemeGen”), a leading Chinese biopharmaceutical company, announced today that it has entered into an agreement with Santen Pharmaceutical (China) Co., Ltd. (“Santen China”), a wholly-owned subsidiary of Santen Pharmaceutical Co., Ltd. (“Santen”). Under the agreement, Santen China has obtained exclusive rights to develop, manufacture, and commercialize RC28-E in Greater […]